No­var­tis buys a new gene ther­a­py for vi­sion loss, and this is one pre­clin­i­cal ven­ture that did­n't come cheap

Cyrus Moza­yeni got ex­cit­ed when he be­gan to ex­plore the aca­d­e­m­ic work of Ehud Isacoff and John G. Flan­nery at UC Berke­ley.

To­geth­er, they were en­gaged in find­ing a gene ther­a­py ap­proach to pan-geno­typ­ic vi­sion restora­tion in pa­tients with pho­tore­cep­tor-based blind­ness, po­ten­tial­ly restor­ing the vi­sion of a broad group of pa­tients. And they did it by us­ing a vec­tor to de­liv­er the ge­net­ic se­quence for light sens­ing pro­teins.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER